BSE filing, NSE: ADIRASA. Summary written from the filing by ALFA Finder's alert engine.
Genpharmasec Ltd: key numbers
- Share price
- ₹0.97
- Market cap
- ₹53.71 Cr
- Revenue (annual)
- ₹139.9 Cr
- Net profit (annual)
- ₹1.60 Cr
- P/E (TTM)
- -440.9×Sector 46.1×
- Promoter holding
- 32.06%+2.08% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Genpharmasec Ltd
All →Genpharmasec Other Announcement
Genpharmasec Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing provides a standard breakdown of promoter and public shareholding.
Genpharmasec Annual General Meeting
Genpharmasec Limited conducted its 34th Annual General Meeting on September 29, 2026. Shareholders considered resolutions including the adoption of FY26 financial statements and director re-appointments.
Genpharmasec Annual Report
Genpharmasec Ltd filed its 34th Annual Report for FY 2025-26 with BSE, including the AGM notice for 29 September 2026. The report covers audited financials, board updates, and governance disclosures.
Genpharmasec Management Change
Genpharmasec Limited has re-appointed Sohan Chaturvedi as Executive Director for a 36-month term effective April 26, 2027. This change is approved by the Board.
Genpharmasec Annual General Meeting
Genpharmasec Limited has announced the closure of its share transfer books from September 23 to 29, 2026, for the 34th Annual General Meeting.
Genpharmasec Promoter Buying: ₹0.71 Cr
Promoter and Director Rajesh Sadhwani acquired 65,00,000 equity shares via market purchase. This increases his stake from 14.09% to 15.26% in Genpharmasec Ltd.
- Value
- ₹0.71 Cr
- Promoter stake change
- +1.17%
Other board meeting outcome announcements
All →R R Kabel Board Meeting Outcome
RR Kabel's board approved amendments to its UPSI fair disclosure code on 28 October 2026. The amended code is enclosed and posted on the company website.
M K Exim (India) Board Meeting Outcome
M.K. Exim (India) approved shifting its registered office within Jaipur to Plot J-1247, Sitapura. The board meeting was held on October 28, 2026.
United Spirits Board Meeting Outcome
United Spirits' board approved amendments to its insider trading code on 28 October 2026, effective 29 October 2026. The revised code is available on the company website.
SBI Funds Management Board Meeting Outcome
SBI Funds Management extended internal auditor Chhajed & Doshi's term to March 31, 2030. This routine decision was taken at the October 28, 2026 board meeting.
- Execution
- April 1, 2028 to March 31, 2030
Paras Healthcare Board Meeting Outcome
Paras Healthcare filed its board-approved UPSI fair disclosure code under Regulation 8(2). This routine governance policy update reports no business event.
Gateway Distriparks Board Meeting Outcome
Gateway Distriparks' board approved a revised Code of Practices for Fair Disclosure of UPSI under PIT Regulation 8(2). This is a routine governance policy update with no business event.